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Abstract
Anti-nicotine vaccines may aid smoking cessation via the induction of anti-nicotine antibodies (Ab) which reduce
nicotine entering the brain, and hence the associated reward. Ab function depends on both the quantity (titer) and the
quality (affinity) of the Ab. Anti-nicotine vaccines tested previously in clinical studies had poor efficacy despite high Ab
titer, and this may be due to inadequate function if Ab of low affinity were induced. In this study, we designed and
synthesized a series of novel nicotine-like haptens which were all linked to diphtheria toxoid (DT) as carrier, but
which differed in the site of attachment of linker to nicotine, the nature of linker used, and the handle used to attach
the hapten to DT. The resulting hapten conjugates were evaluated in a mouse model, using CpG (a TLR9 agonist)
and aluminum hydroxide (Al(OH)3) as adjuvants, whereby Ab titers, affinity and function were evaluated using a
radiolabeled nicotine challenge model. A series of additional linkers varying in length, rigidity and polarity were used
with a single hapten to generate additional DT-conjugates, which were also tested in mice. Conjugates made with
different haptens resulted in various titers of anti-nicotine Ab. Several haptens gave similarly high Ab titers, but
among these, Ab affinity and hence function varied considerably. Linker also influenced Ab titer, affinity and function.
These results demonstrate that immune responses induced in mice by nicotine-conjugate antigens are greatly
influenced by hapten design including site of attachment of linker to nicotine, the nature of linker used, and the
handle used to attach the hapten to DT. While both Ab titer and affinity contributed to function, affinity was more
sensitive to antigen differences.
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Introduction
Tobacco use is responsible for approximately six million
deaths annually and poses a substantial burden on public
health worldwide [1]. While the vast majority of adult smokers
wish to quit, approximately 80% of those who attempt to quit on
their own will relapse within the first month of abstinence and
less than 5% will remain abstinent at 6 months [2].
Pharmacological treatments currently used for smoking
cessation are most often nicotine replacement therapies (e.g.,
gums, patches) or prescription drugs that act within the central
nervous systems to reduce nicotine reward and/or symptoms of
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withdrawal. These treatments are beneficial for promoting
short-term abstinence but are only modestly effective over the
long-term, with fewer than one-quarter of treated subjects
remaining abstinent at the end of one year [3,4].
Vaccines targeting nicotine are being developed as an
alternative approach to treat nicotine dependence. For these
vaccines, the putative mechanism of action is that they will
induce anti-nicotine antibodies that bind nicotine in the
periphery, thus reducing the amount of nicotine entering the
brain, which should in turn reduce reward and help break the
addiction cycle [5]. Clinical trials have been conducted with
several different anti-nicotine vaccines that comprise nicotine-
like haptens conjugated to different carriers, and an adjuvant
that is most often an aluminum salt. Two vaccines have
undergone phase 2 clinical testing as monotherapies, namely
NicQβ (Cytos Biotechnology), which uses a virus-like particle
as carrier [6] and NicVax (Nabi Biopharmaceuticals) which
uses a bacterial exoprotein as carrier [7]. In both studies, there
was a lack of efficacy in the intent to treat (ITT) population,
however subgroup analyses showed enhanced long-term
abstinence rate compared to placebo in smokers with the
highest antibody levels [6,7]. This indicated that better overall
vaccine efficacy might be achievable if high antibody levels
could be generated in a greater proportion of subjects.
In previous studies, we evaluated a model anti-nicotine
vaccine comprised of trans-3 ̕-aminomethylnicotine (3 ̕AmNic)
conjugated to diphtheria toxoid (DT) and showed that using two
adjuvants, namely aluminum hydroxide and CpG
oligodeoxynucleotides (CpG, an agonist for Toll-like receptor
9), induced significantly higher anti-nicotine antibody levels in
mice and non-human primates than when aluminum hydroxide
was used as sole adjuvant [8]. When Ab function was
evaluated in mice by intravenous (IV) administration of
radiolabeled nicotine there was only a modest (30%) reduction
of nicotine in the brain compared to non-vaccinated controls,
even with the superior adjuvant formulation that gave
approximately 10-times higher antibody levels. Function was
assessed in non-human primates by determination of the
nicotine binding capacity and when nicotine was added at a
concentration that can be found in arterial blood of a chronic
smoker (100 ng/mL), only 30% was bound, indicating that 70%
would be available to enter the brain. A 30% reduction of
nicotine to the brain is probably not sufficient to impact reward
and indeed a recent study with NicVax, which had previously
failed both phase 2 and phase 3 trials, showed vaccinated
subjects had ~25% reduction of nicotine in their brains [9].
Antibody function depends on both the amount of antibody
(titer) as well as the quality of the antibody (affinity), so further
improvements in function could in theory be achieved with
vaccines that induce even higher antibody titers and/or
antibodies of greater affinity. Antibody titers require the antigen
to be “immunogenic” but in our experience, are largely
influenced by adjuvants, whereas affinity is largely determined
by the antigen but can sometimes be influenced by adjuvants.
Screening using functional assays is the best approach since
the determinants of antibody responses are complex and the
relative roles of titer and affinity are difficult to predict.
In order to render a small molecule such as nicotine
immunogenic, it must be conjugated to a carrier protein, which
provides a scaffold to present nicotine to the immune system,
as well as the required T cell help to stimulate B cell
proliferation and induce antibody class switching. A linker
between the small molecule and the carrier as well as a
‘handle’ that can be used to improve the carrier protein
functionality are also generally required. The identity of hapten
[10–12], carrier protein [10,13], and linker [10,14] can all
contribute to the immunogenicity of the conjugate antigen.
In this study, a series of novel nicotine-like haptens, were
designed with variations in the attachment site on nicotine, the
type of linker, and the handle used to attach the hapten to the
carrier protein, which in all cases was DT. Mice were
immunized with these hapten conjugates adjuvanted with CpG
and aluminum hydroxide (Al(OH)3), and responses were
compared by determination of Ab titers, affinity and function
(using the radiolabeled nicotine challenge model). Based on
these data, 5-amino-ethoxy-nicotine (Hapten 7) was selected
and further used with the DT carrier to evaluate the influence of
linker polarity, rigidity and length on immunogenicity and
function in mice.
Materials & Methods
Ethics Statement
All animal studies were approved by the Institutional Animal
Care and Use Committee of Pfizer Vaccine Research, Ottawa
Laboratories in accordance with the guidelines of the Canadian
Council on Animal Care (CCAC) and the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC).
Antigens
Preparation of Haptens 1-11.  A series of eleven nicotine-
like haptens were tested which differed in the site of
attachment of linker to nicotine, the nature of linker used, and
the handle used to attach the hapten to the carrier protein
(Figure 1). All compounds were prepared by Pfizer, with the
exception of Hapten 11 (trans-3 ̕-aminomethylnicotine, 3 ̕AmNic)
which was purchased from Toronto Research Chemicals, North
York, Ontario, Canada. The routes to synthesize all other
haptens are summarized below. Additional synthetic
procedures for all compounds can be found in Supplementary
Information.
Haptens 1, 5, 6, 7 and 8 were all readily accessible via a
common key intermediate, the boronate ester 2 (Figure 2); this
intermediate could be readily synthesized as a single
regioisomer from nicotine (1) utilizing the method of Hartwig
[15] via iridium-mediated borylation. 2 was readily converted to
bromide 3 using copper (II) bromide (CuBr2) (Figure S1).
Alcohol 6 was accessed from 2 via oxidative cleavage with
hydrogen peroxide (H2O2) and acetic acid (AcOH); in this
reaction, the presence of the acid was key to prevent the
pyridine nitrogen being oxidized (Figure S16, Figure S17). 6
was then alkylated with bromide 7 and deprotected to provide
Hapten 7 (Figure S18, Figure S19). The bromide 3 was used to
synthesize a range of linking groups which could be readily
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appended via palladium coupling. Heck coupling of methyl
acrylate followed by hydrogenation and hydrolysis allowed
access to the sodium salt of Hapten 1 (Figure S2, Figure S3,
Figure S4) while coupling with acrylonitrile and reduction
allowed access to Hapten 6 (Figure S5, Figure S6, Figure S7).
Functionalisation at the 2- and 6-positions of nicotine was
achieved using the methodology of Comins [16]. Lithiation with
n-butyl lithium /lithium dimethylethanolamine (n-BuLi/LiDMAE)
[17], followed by quenching into hexachloroethane gave a
mixture of 2- and 6-substituted chloronicotines 13 and 14
(Figure S11) which were converted to Haptens 2 and 3
respectively by heating with the sodium alkoxide of
ethanolamine (Figure S12, Figure S13). Lithiation at the 4-
position was accomplished using Trimethylsilylmethyllithium
(TMSCH 2Li) [18]; quenching with hexachloroethane gave
chloride 9 (Figure S14). Subsequent reaction with the sodium
alkoxide of ethanolamine gave the 4-substituted Hapten 4
together with some undesired alcohol, 10 (Figure S15).
Ester 5 could be converted to the thioacetate Hapten 8 via
reduction, mesylation and displacement with potassium
thioacetate (Figure 3) (Figure S8, Figure S9, Figure S10).
Cleavage of the acetate group was not carried out as the thiol
was found to readily oxidise to the corresponding disulfide in
situ and so the group was cleaved at the point of coupling to
the carrier protein.
Palladium catalyzed coupling of zinc cyanide with bromide 3
allowed access to nitrile 17 which following hydrolysis, amide
coupling and tert-butyloxycarbonyl (BOC) deprotection gave
Hapten 5 (Figure 4) (Figure S24, Figure S25, Figure S26,
Figure S27).
Hapten 9 was synthesized using a modification of the
method of Ullrich [19].
Dibromopyridine 21 was metallated with lithium
diisopropylamide (LDA) and quenched with methyl formate to
give aldehyde 22 (Figure S28) which was converted through to
ester 24 via Wittig reaction and hydrogenation over rhodium on
alumina (Figure 5) (Figure S29, Figure S30). Ester 24 was
reacted with the enolate of lactam 25 to give ketoamide 26
(Figure S31). Acidic hydrolysis with concomitant
decarboxylation and condensation gave imine 27 (Figure S32)
which was metallated with butyllithium leading to in situ ring-
closure to give racemic spiro amine 28 (Figure S33).
Methylation under reductive amination conditions gave 29
(Figure S34) while subsequent Heck coupling, hydrogenation
and basic hydrolysis generated Hapten 9 as a racemic mixture
(Figure S35, Figure S36, Figure S37).
Hapten 10 was synthesised via the commercially available
bromide 32 utilising similar methodology to the previous
compounds (Figure 6) (Figure S20, Figure S21, Figure S22,
Figure S23).
The degree of hapten coupling to DT was measured for all
haptens using a reverse-phase HPLC (RP-HPLC) method
utilizing a Waters C-18 X-Bridge column with a gradient of
0.1% triethylamine (TEA): 0.1% TEA in methanol (Table 1). In
this process, haptens were uncoupled from DT by acid
hydrolysis and analysis of pre-hydrolysis and post-hydrolysis
Figure 1.  Nicotine and hapten structures.  The thioacetate of Hapten 8 was deprotected to the thiol for coupling with DT.
doi: 10.1371/journal.pone.0076557.g001
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levels used to determine the degree of conjugation per unit
loading of DT.
Preparation of Haptens 7.L1 to 7.L12: General
Scheme.  Linkers of different polarity, length and rigidity were
Figure 2.  Synthesis of Haptens 1, 2, 3, 4, 6 and 7.  
doi: 10.1371/journal.pone.0076557.g002
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appended to Hapten 7 to yield a series of linker modified
haptens (designated Hapten 7.L1 to Hapten 7.L12, Figure 7)
using the general scheme depicted in Figure 8.
Haptens 7.L2 to 7.L12 were prepared according to the
following general procedure:
Hapten 7 was dissolved in 2-methyltetrahydrofuran (2-
MeTHF) to which was added the acid-functionalised linker,
coupling agent 2,4,6-Tripropyl-1,3,5,2,4,6-
trioxatriphosphorinane-2,4,6-trioxide (T3P®) and triethylamine
(Et 3N). The reactions were stirred at room temperature (RT)
under nitrogen for 16 hours and were then evaporated in vacuo
to leave orange oils. These were dissolved in methanol
(MeOH) and run through a 5 g SCX cartridge eluting with
MeOH, then 4:1 MeOH: Ammonia (7M in MeOH). The
appropriate fractions were evaporated in vacuo and
chromatographed on 4 g ISCO cartridges eluting with mixtures
of dichloromethane (DCM), MeOH and ammonia (NH3) and
evaporated in vacuo to yield the protected haptens that were
used in the next step without further purification or
characterization.
The protected version of Hapten 7.L1 was prepared from
diethyl squarate, which was dissolved in ethanol (EtOH) and
treated with BOC-ethylenediamine, Hünigs base and Hapten 7
and the reaction stirred at RT for 16 hours. The mixture was
evaporated in vacuo to leave an orange oil that was dissolved
in MeOH and run through a 5 g SCX cartridge eluting with
MeOH, then 4:1 MeOH: Ammonia (7M in MeOH). The
appropriate fractions were evaporated in vacuo and
chromatographed as above.
BOC-protected amines were deprotected to yield Haptens
7.L1 to 7.L12 by dissolving in DCM and cooling to 0 °C. To this
cooled solution, trifluoroacetic acid (TFA) was added and the
reaction was allowed to warm to RT and stirred for 16 hours.
The reaction mixtures were evaporated in vacuo to leave
orange gums that were dissolved in MeOH and loaded onto 5 g
SCX cartridges and eluted with MeOH, then 4:1 MeOH:
Ammonia (7M in MeOH). The solutions were evaporated under
reduced pressure to yield the haptens depicted in Figure 7.
The degree of hapten coupling to DT was measured for all
haptens as outlined above (Table 2).
Conjugation of Haptens to Diphtheria Toxoid.  Diphtheria
Toxoid (DT; Pfizer, Lincoln, NE) in Dulbecco’s Phosphate
Buffered Saline (DPBS, Gibco, Grand Island, NY) was first
derivatised with succinic anhydride (Acros, Pittsburgh, PA)
Figure 3.  Synthesis of Hapten 8.  
doi: 10.1371/journal.pone.0076557.g003
Figure 4.  Synthesis of Hapten 5.  
doi: 10.1371/journal.pone.0076557.g004
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added as powder. The reaction mixture was incubated for two
hours at RT and post-incubation excess succinic anhydride and
reaction by-products were removed by buffer exchange into
DPBS (using a Nap-25 desalting column, Pierce, Rockford, IL).
An excess of the desired hapten (solubilised in DPBS) was
added to the succinylated DT, along with an equal weight of 1-
ethyl-3-(3-diethylamino)propyl carbodiimide hydrochloride
(EDC) (Pierce, Rockford, IL) and sulfo N-hydroxysuccinimide
(sNHS) (Sigma Aldrich, St Louis, MO). The conjugation
reaction was incubated for two hours at room temperature to
yield the hapten-DT conjugate. Post-conjugation, excess
reagents and reaction bi-products were removed by buffer
exchange into DPBS (Nap-25 Column, Pierce) prior to storage
at 2-8 °C.
Adjuvants
The adjuvants used were a B Class CpG ODN (CpG) of
sequence 5’ TCG TCG TTT TTC GGT GCT TTT 3’, which was
synthesized with a wholly nuclease-resistant phosphorothioate
backbone (Pfizer, St. Louis, MI), and Al(OH)3 (Alhydrogel “85”,
Brenntag Biosector, Denmark).
Immunizations
Female BALB/c mice (Charles River Laboratories, Montreal,
QC, n=10/group) were immunized with 10 µg of Hapten-DT
conjugate in combination with Al(OH)3 (40 µg Al3+) and CpG
(50 µg) made up to a total volume of 50 µl with phosphate
buffered saline (PBS; Sigma Chemical Co., St. Louis, MO).
Preliminary studies had demonstrated that these doses of
antigen and adjuvants were appropriate for screening
purposes. The vaccine formulations were administered by
Figure 5.  Synthesis of Hapten 9.  
doi: 10.1371/journal.pone.0076557.g005
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intramuscular (IM) injection in the left tibialis anterior (TA)
muscle of mice lightly anaesthetized with Isoflurane® (CDMV,
St. Hyacinthe, QC) on days 0, 28 and 42. Animals were bled on
days 27, 41 and 54 by submandibular venus puncture using
heparin as an anti-coagulant and recovered plasma used for
quantitation of nicotine-specific immune responses. All groups
were repeated on at least one occasion to ensure
reproducibility of results.
Using a single Hapten-DT conjugate, female Sprague
Dawley rats (Charles River Laboratories, Montreal, QC, n=5/
group) were immunized with 0.4 mg of Hapten7-DT conjugate
in combination with Al(OH)3 (0.4 mg Al3+) and CpG (0.5 mg)
made up to a total volume of 500 µl with phosphate buffered
saline (PBS; Sigma Chemical Co., St. Louis, MO). The vaccine
formulations were administered as above on days 0, 28, 56, 84
and 112. Animals were bled two weeks following last dose and
recovered plasma used for quantitation of nicotine-specific
immune responses.
Anti-nicotine antibody ELISA
The levels of anti-nicotine IgG antibodies in mouse plasma
were quantified by endpoint ELISA (in triplicate) for individual
animals using 96-well plates coated with a nicotine derivative
(rac-trans-3’-thio methyl nicotine dihydrochloride) conjugated to
bovine serum albumin as previously described [8]. Titers were
calculated as the dilution corresponding to an absorbance
reading 50% of the maximal value using GraphPad Prism
(GraphPad Software, San Diego, CA).
Antibody Affinity by Competition ELISA
The relative affinity of antibodies was determined by
competition ELISA as previously described [8]. In brief, plasma
samples, previously determined to contain anti-nicotine
antibodies, were diluted to achieve absorbance values of
approximately 1.0-1.5 at 450 nm; and nicotine was serially
diluted starting at 20,000 µM. Equal volumes of diluted samples
and nicotine were incubated for 1 hour at 37 °C, added to
nicotine-BSA coated plates and antibody binding determined.
OD readings at 450 nm were plotted against the molar
concentration of nicotine and the 50% inhibition (IC50) was
extrapolated for each sample tested. For rat samples, a
modification of this assay was used whereby mean fluorescent
intensity was measured using a Luminex-based microbead
assay with nicotine added over a range of concentrations from
0.2 to 20 µM. Percent inhibition was calculated at each
concentration of nicotine and the 50% inhibition (IC50) was
interpolated for each sample tested.
In Vivo Functional Assay: Nicotine Distribution in Brain
and Plasma
The function of anti-nicotine Ab in immunized mice was
evaluated by assessing nicotine distribution in the brain and
plasma following tail vein infusion (<5 seconds) of 0.05 mg/kg
of nicotine hydrogen tartrate (Sigma-Aldrich) containing 3 µCi
3H-nicotine (PerkinElmer) in 100 µL of PBS as previously
described [8]. The 0.05 mg/kg dose of nicotine used is
Table 1. Hapten Loading of Different Hapten-DT
Conjugates.
Hapten # Hapten Loading (per unit DT)
1 5
2 14
3 19
4 3
5 15
6 19
7 13
8 N/A*
9 2
10 6
11 9
*. N/A – not available
doi: 10.1371/journal.pone.0076557.t001
Figure 6.  Synthesis of Hapten 10.  
doi: 10.1371/journal.pone.0076557.g006
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considered approximately equivalent to the mg/kg dose of
nicotine delivered to a human by three smoked cigarettes [20].
Ex Vivo Functional Assay: Nicotine-binding Capacity of
Anti-nicotine Antibodies
The function of anti-nicotine Ab in immunized rats was
evaluated by assessing nicotine-binding capacity using an
equilibrium dialysis method [8]. In brief, plasma collected after
vaccine dosing was spiked with a fixed amount of nicotine
equivalent to high blood levels in smokers (100 ng/mL) and
then subjected to equilibrium dialysis against DPBS for 3 h at
37°C using Spectrapor 4 membranes with a molecular weight
cutoff of 12 to 14 kDa and 20 Micro-cell Equilibrium Dialyzer
(Spectrum Labs, Rancho Dominguez, CA). The 100 ng/mL
spiking dose of nicotine was selected as this represents a high
concentration of nicotine in the arterial blood of a heavy
Figure 7.  Structures of different linker-modified nicotine hapten.  
doi: 10.1371/journal.pone.0076557.g007
Design of a Novel Anti-Nicotine Vaccine
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e76557
smoker. Using nicotine-d3 as internal standard, aliquots from
the sample and buffer sides of dialysis membrane were
extracted using a protein precipitation extraction procedure.
The extracted samples were then injected into an HPLC
equipped with Applied Biosystems API 4000 LC/MS/MS
system and concentrations of bound and unbound nicotine
determined.
Statistical analysis
Data were analyzed using GraphPad Prism. Statistical
significance of the difference between groups was calculated
by 1-factor analysis of variance (ANOVA) followed by post-hoc
analysis. Differences were considered to be not significant with
p>0.05.
Results
Effect of Hapten Design on Immunogenicity of Hapten-
DT conjugates
Pilot studies showed very poor antibody responses were
induced in mice when conjugates were administered without an
adjuvant, therefore for comparison of conjugates in this study,
each was administered together with aluminum hydroxide and
CpG adjuvants.
All adjuvanted nicotine hapten conjugates generated
nicotine-specific antibodies in mice, however levels varied
depending on hapten design (p = 0.0002) (Figure 9, Panel A).
Overall, the highest levels of nicotine-specific IgG were
obtained with Hapten 11-DT (p<0.05 compared to all other
conjugates), although Haptens 1, 2, 3, 5, 6, 7 or 8 DT
conjugates were also able to induce high levels of anti-nicotine
antibodies (titer ≥105). Lowest levels were induced by Hapten
4-DT and Hapten 9-DT (p<0.05 compared to all other
conjugates). In addition, antibody affinity varied depending on
hapten conjugate tested with equivalent affinity (<20 µM)
induced by conjugates containing Haptens 1, 2, 3, 5, 6, 7, 8
and the weakest affinity antibodies (>150 µM) induced by those
containing Haptens 10 and 11 (Table 3). Ab titers for
conjugates containing Haptens 4 or 9 were too low to
determine affinity.
The in vivo function of the anti-nicotine antibodies in mice, as
assessed by IV administration of radiolabeled nicotine, also
varied with different hapten conjugates (p < 0.0001 and p =
0.0002, for plasma and brain, respectively). Hapten conjugates
containing Haptens 2, 3, 6, 7 and 11 significantly increased
levels of nicotine in the blood compared to non-immunized
animals (p<0.05) (Figure 9B), and hapten conjugates
containing Haptens 2, 5, 6, 7 and 8 significantly decreased
levels of nicotine in the brain (p<0.05) (Figure 9C). Overall best
responses were obtained with conjugates containing Haptens
2, 6 or 7 that had ~130, 81 and 156% greater retention of
nicotine in the plasma, and 36, 27 and 40% decrease of
nicotine in the brain, respectively, as compared to control
animals.
As expected, Ab function depended on both Ab titer and
affinity with the best responses being obtained with conjugates
that induced both high Ab levels and good affinity. In contrast,
Table 2. Hapten Loading of Different Hapten 7-DT
Conjugates.
Hapten # Hapten Loading (per unit DT)
7.L1 19
7.L2 23
7.L3 21
7.L4 19
7.L5 4
7.L6 24
7.L7 20
7.L8 14
7.L9 12
7.L10 13
7.L11 29
7.L12 11
doi: 10.1371/journal.pone.0076557.t002
Figure 8.  General scheme for addition of different linkers to Hapten 7.  
doi: 10.1371/journal.pone.0076557.g008
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conjugates that induced either low Ab levels or poor affinity,
even in the presence of high titers (e.g., Hapten 11-DT)
resulted in poor functional results. Not every conjugate that
induced good Ab responses and affinity resulted in good
function, and it is possible this resulted from the relatively low
sensitivity of the ELISA assay used to measure affinity in this
study; in more recent studies we have found improved
differentiation of affinity with Luminex based methods.
Hapten loading was determined for all conjugates (Table 1)
and compared with antibody titer, affinity and function.
However, while there was some degree of correlation with Ab
function, as measured by concentration of nicotine in the brain
(r2 = 0.55), there was only a weak correlation with antibody
Figure 9.  Anti-nicotine antibody titer and function in mice.  Panel A: BALB/c mice (n = 12/gp) were immunized by IM injection
with 10 µg of different nicotine Hapten-DT conjugates adjuvanted with Al(OH)3 (40 µg Al3+) + CpG 24555 (50 µg) on days 0, 28 and
42. Plasma was collected on day 54 and anti-nicotine antibody levels determined by ELISA (Panel A). On day 56 animals received
an IV injection of 3H-nicotine (0.05 mg/kg) and plasma and brains collected. Panel B shows nicotine levels in plasma (ng-eq/mL),
and Panel C shows nicotine levels in brain (ng-eq/g).
doi: 10.1371/journal.pone.0076557.g009
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levels (r2 = 0.34) and no correlation with antibody affinity (r2 =
0.04).
Effect of Linker on Immunogenicity of Hapten 7-DT
conjugates
Since strong functional results were obtained with the
Hapten 7-DT conjugate, Hapten 7 was chosen to investigate
the effect of additional linker modifications including effect of
polarity, length and rigidity. All linker modified Hapten 7
conjugates generated nicotine-specific Abs in mice, but levels
varied depending on linker used (p < 0.0001) (Figure 10). None
of the linker modified Hapten 7 conjugates gave levels of
nicotine-specific Abs that were higher than those obtained with
unmodified Hapten 7-DT, and those conjugates having rigid
linkers (Hapten 7.L5, Hapten7.L1), or longer chain hydrophilic
linkers (Hapten 7.L3, Hapten 7.L6 and Hapten 7.L10) gave
significantly lower Ab levels (p<0.05). There was no significant
difference in affinity between the linker modified Hapten 7
conjugates and Hapten 7-DT (p>0.05), with all having a
measured IC50 of ~20 µM.
The in vivo function of the anti-nicotine Abs also varied with
different linker modified Hapten 7 conjugates (p < 0.0001, for
plasma and brain) (Figure 10). Although most of the linker
modified Hapten 7 conjugates (with the exception of Hapten 7-
L1 and Hapten 7.L5) resulted in decreased nicotine in the brain
and increased nicotine in the plasma compared to control
animals (p<0.05), none of them gave a better functional
response than was obtained with Hapten 7-DT that had ~220%
greater retention of nicotine in the plasma, and 60% decrease
of nicotine in the brain, respectively, as compared to control
animals. Hapten 7 conjugates with rigid linkers (Hapten 7.L5,
Hapten 7.L1), gave a significantly weaker response than was
obtained with Hapten 7-DT (p<0.05).
Hapten loading was determined for all conjugates (Table 2)
and compared with antibody titer and function. However, there
was no correlation observed with either antibody levels (r2 =
0.02) or antibody function, as measured by concentration of
nicotine in the brain (r2 = 0.14), most likely since most
conjugates had a similar levels of hapten loading.
Since best responses were obtained in mice using the
Hapten 7-DT conjugate without the use of an additional linker,
Table 3. Relative Affinity of Anti-Nicotine Antibodies
induced by Different Hapten-DT Conjugates in Mice.
Hapten # IC50 (µM) SEM
1 19.2 3.2
2 8.7 0.7
3 15.4 1.6
5 15.2 3.6
6 18.7 1.8
7 20.9 8.0
8 17.4 5.9
10 163.4 11.6
11 211.2 86.8
doi: 10.1371/journal.pone.0076557.t003
this conjugate was also evaluated in rats to assess the
nicotine-binding capacity using an equilibrium dialysis method.
At a spiking dose of 100 ng/mL (equivalent to high blood levels
in smokers), approximately 100% of nicotine (95 ± 3.5%) was
bound in serum from immunized rats with a mean IC50 of 0.95 ±
1.31 µM.
Discussion
In recent years a number of anti-nicotine vaccines have been
evaluated in the clinic. Of these, the greatest experience has
been with NicVax (Nabi Pharmaceuticals) followed by NicQb
(Cytos Biotechnology). Despite failure to improve long-term quit
rates in the intent-to-treat population, there was some evidence
to support the putative mechanism in that a subset of subjects
with the highest Ab titers had significantly higher quit rates at 1
year compared to placebo [7]. It appears that both vaccines
were developed to induce high anti-nicotine Ab titers so it is
possible that, assuming the putative mechanism is sound, low
affinity Ab may have contributed to the poor efficacy. It should
also be noted that with both NicVax and NicQb, as is the case
in all anti-nicotine vaccines, antibodies are generated against
nicotine-derived haptens and not against nicotine per se. Thus,
a high antibody titer generated by such vaccines may not
necessarily reflect a strong ability to bind to nicotine in the
blood; this highlights the importance of screening using
functional assays such as drug distribution following nicotine
challenge rather than just immunogenicity read-outs.
In attempts to improve anti-nicotine vaccine efficacy, a
number of different approaches have been used including
modifications of hapten structure [10–12], composition and
position of linker [10,14], carrier protein [10,13], adjuvant [21],
route of administration [21,22] and co-administration of more
than one nicotine hapten conjugate [13]. All of these
approaches have to some extent altered the immunogenicity of
nicotine vaccines, at least in pre-clinical models. We have
previously shown that adjuvant combinations such as Al(OH)3
and CpG can enhance the function of anti-nicotine vaccines
through augmenting both antibody titer and affinity [8]. Herein
using the same adjuvant combination previously tested (CpG/
Al(OH)3), we evaluated the impact of antigen design on
functional responses.
The pyrrolidine ring of nicotine has most commonly been
used as the site of linker attachment to nicotine. The 3̕-position
was first used to generate trans-3 ̕-succinyl-methyl nicotine by
Langone et al in the early 1970s in attempts to create
radioimmunoassay detection reagents [23], and since then the
pyrrolidine ring has been used as the site of linker attachment
in many pre-clinical anti-nicotine vaccine studies
[11,22,24–27]. . Both NicVax and NicQb, utilize conjugation via
the 3 ̕-position on the pyrrolidine ring of nicotine to
Pseudimonas aeroginosa recombinant exoprotein A (NicVax)
and a virus-like particle of bacteriophage Qb (NicQb),
respectively. In our study, we evaluated the same nicotine
hapten as used in NicVax (3 ̕AmNic) conjugated to DT via the 3 ̕-
position on the pyrrolidine ring (Hapten 11), and compared this
to a number of different haptens which varied in hapten design,
linker, handle and site of attachment but which were all
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attached to DT via the pyridine ring. Of the 11 haptens tested,
Hapten 11 induced the highest levels of Ab, but this did not
translate to best functional responses. Previous studies have
suggested that higher antibody titers can compensate for
weaker affinity [12], however our data showed that even very
high titers of low affinity antibodies were functionally inferior to
lower titers of higher affinity antibodies. Our results suggested
that an intact and unhindered pyrrolidine ring was essential for
good functional responses since conjugates whose haptens
had the pyrrolidine ring replaced by piperidine (Hapten 10),
constrained (Hapten 9) or used as site of attachment to DT
(Hapten 11) resulted in poor immunogenicity (low Ab titer and
affinity) and function (high nicotine in brain). Poor responses
were also obtained with Hapten 4, which was attached to DT at
the 4-position of the pyridine ring, the closest available position
to the pyrrolidine ring. In contrast, Hapten 3 which was linked to
DT through the 2-position, distal to that used for Hapten 4, had
a very different Ab and affinity response. Previous studies have
shown that constrained haptens can increase both antibody
titer and affinity compared to unconstrained haptens, however
our data do not support this [12]. Differences in how the hapten
is constrained as well as carrier and adjuvants may account for
this discrepancy.
It was previously proposed that attachment to nicotine via the
pyridine ring was preferable as this might increase the
specificity for antibodies for nicotine rather than its metabolites
Figure 10.  Anti-nicotine antibody titer and function in mice.  Panel A: BALB/c mice (n = 12/gp) were immunized by IM injection
with 10 µg of different nicotine Hapten-DT conjugates adjuvanted with Al(OH)3 (40 µg Al3+) + CpG 24555 (50 µg) on days 0, 28 and
42. Plasma was collected on day 54 and anti-nicotine antibody levels determined by ELISA (Panel A). On day 56 animals received
an IV injection of 3H-nicotine (0.05 mg/kg) and plasma and brains collected. Panel B shows nicotine levels in plasma (ng-eq/mL),
and Panel C shows nicotine levels in brain (ng-eq/g).
doi: 10.1371/journal.pone.0076557.g010
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[28]. Haptens 2, 3, 4 and 7 were all conjugated via the pyridine
ring using the same aminoethoxy linker at each of the four
different free positions on the pyridine ring (positions 6, 2, 4
and 5 respectively), and when tested in mice, the best
response overall was obtained with linker attachment at the 5-
position, good responses at the 6- or 2-positions and poor
responses at the 4-position. These results indicate that not only
is the ring important but also the exact site of linkage on that
ring. Similar results have been reported previously, although in
that case the 6-position was deemed best in contrast to the 5-
position in the present study [14]. This discrepancy may be
partly due to the different linkers and readouts used in the two
studies.
The impact of different linkers and chemical handles on the
5-position as site of attachment was evaluated by comparing
aminoethoxy (Hapten 7), aminopropyl (Hapten 6), carboxyl
ethyl (Hapten 1), propanethiol (Hapten 8), and an amide-
containing linker (Hapten 5). The best functional response was
obtained with the aminoethoxy linker, although good responses
were also obtained using the aminopropyl linker, whereas
weaker responses were seen with other linkers/handles.
Hapten loading has previously been shown to be influential
in determining immunogenicity of conjugate vaccines [29]. We
demonstrated that hapten loading correlated to some extent
with vaccine immunogenicity, suggesting that responses with
some of our poorer conjugates could have been improved had
hapten loading been optimized.
Linker length and flexibility have previously been reported as
influential in determining the efficacy of anti-nicotine [10,14]
and anti-methamphetamine vaccines [30], and in the elicitation
of functional monoclonal Abs that bind methamphetamine
[31,32]. Therefore we systematically investigated a series of
different linkers which varied in length, polarity and flexibility.
The synthetic complexity of the linker-hapten construct was
also taken into consideration during the vaccine design, such
that difficult-to-synthesize longer linkers were not pursued.
Interestingly, we saw no significant improvement in responses
with the additional linkers, and, in particular with the use of
hydrophilic linkers, increased length appeared to result in the
induction of weaker immune responses, possibly in an
analogous manner to the reduced immunogenicity of
PEGylated proteins [33]. Our weakest responses were
obtained with the use of rigid linkers, namely the cyclohexyl
(Hapten 7.L5) and squaramide tethers (Hapten 7.L1)
suggesting that Ab generation and avidity is favoured by
shorter and more flexible linkers. Previous studies using a
derivative of Lipid A conjugated to KLH incorporating a similar
bis-cyclohexyl linker to that used in Hapten7. L5 have
demonstrated that active immunization with conjugates
containing this linker could enhance antibody levels and induce
significant protection against the effects of E. Coli lipid A in a
murine model [34]. Also, squaramide-based coupling chemistry
has been used extensively in the area of bioconjugation [35]
and a squaramide-containing reactive immunogen has been
used previously to generate monoclonal antibodies as tools for
the investigation of paraoxon poisoning [36]. It is possible that
the use of these linkers may have shifted the dominant epitope
away from the nicotine hapten and onto the linker itself
(especially as the squaramide motif is formally aromatic in
nature); however, confirmation of this hypothesis was outside
the scope of the current study. In the current study, a single
carrier protein was used to evaluate multiple haptens and
linkers. However, carrier itself can influence the
immunogenicity of the conjugate and it is possible that the
relative effects of the different linkers may have differed with a
different carrier. In this study in rats, using Hapten7 conjugated
to DT, we were able to induce antibodies with 100% nicotine
binding at 100 ng/mL. However, in separate studies in non-
human primates, using a modified Hapten7 conjugate vaccine
with the same adjuvant combination, we have subsequently
been able to obtain 100% binding with a ten-fold higher amount
of nicotine (1000 ng/mL) [37].
Overall, these results demonstrate that immune responses
induced in mice by nicotine-conjugate antigens are greatly
influenced by hapten design including site of attachment of
linker to nicotine, the nature of linker used, and the handle
used to attach the hapten to DT. While both Ab titer and affinity
contributed to function, affinity was more sensitive to antigen
differences. Our work suggests that, assuming the basic
concept of anti-nicotine vaccines is sound, better clinical
outcomes may be realized using antigens selected for their
ability to induce antibodies of both high titer and high affinity,
especially when combined with adjuvants that strongly
enhance both aspects.
Supporting Information
Figure S1.  Preparation of (S)-3-bromo-5-(1-
methylpyrrolidin-2-yl)pyridine.
(TIF)
Figure S2.  Preparation of (S,E)-methyl 3-(5-(1-
methylpyrrolidin-2-yl)pyridin-3-yl)acrylate.
(TIF)
Figure S3.  Preparation of (S)-methyl 3-(5-(1-
methylpyrrolidin-2-yl)pyridin-3-yl)propanoate.
(TIF)
Figure S4.  Preparation of (S)-3-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yl)propanoic acid (Hapten 1).
(TIF)
Figure S5.  Preparation of (S)-3-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yl)acrylonitrile.
(TIF)
Figure S6.  Preparation of (S)-3-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yl)propanenitrile.
(TIF)
Figure S7.  Preparation of (S)-3-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yl)propan-1-amine (Hapten 6).
(TIF)
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Figure S8.  Preparation of (S)-3-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yl)propan-1-ol.
(TIF)
Figure S9.  Preparation of (S)-3-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yl)propyl methanesulfonate.
(TIF)
Figure S10.  Preparation of (S)-S-3-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yl)propyl ethanethioate (Hapten 8).
(TIF)
Figure S11.  Preparation of (S)-2-chloro-5-(1-
methylpyrrolidin-2-yl)pyridine or 6-chloronictone and (S)-2-
chloro-3-(1-methylpyrrolidin-2-yl)pyridine or 2-
chloronicotine.
(TIF)
Figure S12.  Preparation of (S)-2-(5-(1-methylpyrrolidin-2-
yl)pyridin-2-yloxy)ethanamine (Hapten 2).
(TIF)
Figure S13.  Preparation of (S)-2-(3-(1-methylpyrrolidin-2-
yl)pyridin-2-yloxy)ethanamine (Hapten 3).
(TIF)
Figure S14.  Preparation of (S)-4-chloro-3-(1-
methylpyrrolidin-2-yl)pyridine or 4-chloronicotine.
(TIF)
Figure S15.  Preparation of (S)-2-(3-(1-methylpyrrolidin-2-
yl)pyridin-4-yloxy)ethanamine (Hapten 4) and (S)-2-(3-(1-
methylpyrrolidin-2-yl)pyridin-4-ylamino)ethanol.
(TIF)
Figure S16.  Preparation of (S)-3-(4-methoxybenzyloxy)-5-
(1-methylpyrrolidin-2-yl)pyridine.
(TIF)
Figure S17.  Preparation of (S)-5-(1-methylpyrrolidin-2-
yl)pyridin-3-ol or 5-hydroxynicotine.
(TIF)
Figure S18.  Preparation of (S)-tert-butyl 2-(5-(1-
methylpyrrolidin-2-yl)pyridin-3-yloxy)ethylcarbamate.
(TIF)
Figure S19.  Preparation of (S)-2-(5-(1-methylpyrrolidin-2-
yl)pyridin-3-yloxy)ethanamine (Hapten 7).
(TIF)
Figure S20.  Preparation of (S)-3-bromo-5-(1-
methylpiperidin-2-yl)pyridine.
(TIF)
Figure S21.  Preparation of (S,E)-methyl 3-(5-(1-
methylpiperidin-2-yl)pyridin-3-yl)acrylate.
(TIF)
Figure S22.  Preparation of (S)-methyl 3-(5-(1-
methylpiperidin-2-yl)pyridin-3-yl)propanoate.
(TIF)
Figure S23.  Preparation of (S)-3-(5-(1-methylpiperidin-2-
yl)pyridin-3-yl)propanoic acid, sodium salt (Hapten 10).
(TIF)
Figure S24.  Preparation of (S)-5-(1-methylpyrrolidin-2-
yl)nicotinonitrile or 5-cyanonicotine.
(TIF)
Figure S25.  Preparation of (S)-5-(1-methylpyrrolidin-2-
yl)nicotinic acid.
(TIF)
Figure S26.  Preparation of (S)-tert-butyl 2-(5-(1-
methylpyrrolidin-2-yl)nicotinamido)ethylcarbamate.
(TIF)
Figure S27.  Preparation of (S)-N-(2-aminoethyl)-5-(1-
methylpyrrolidin-2-yl)nicotinamide (Hapten 5).
(TIF)
Figure S28.  Preparation of 3,5-dibromoisonicotinaldehyde.
(TIF)
Figure S29.  Preparation of (E)-methyl 3-(3,5-
dibromopyridin-4-yl)acrylate.
(TIF)
Figure S30.  Preparation of Methyl 3-(3,5-dibromopyridin-4-
yl)propanoate.
(TIF)
Figure S31.  Preparation of 3-(3-(3,5-dibromopyridin-4-
yl)propanoyl)-1-vinylpyrrolidin-2-one.
(TIF)
Figure S32.  Preparation of 3,5-dibromo-4-(2-(3,4-
dihydro-2H-pyrrol-5-yl)ethyl)pyridine.
(TIF)
Figure S33.  Preparation of 4-bromo-5,6-
dihydrospiro[cyclopenta[c]pyridine-7,2'-pyrrolidine].
(TIF)
Figure S34.  Preparation of 4-bromo-1'-methyl-5,6-
dihydrospiro[cyclopenta[c]pyridine-7,2'-pyrrolidine].
(TIF)
Figure S35.  Preparation of (E)-methyl 3-(1'-methyl-5,6-
dihydrospiro[cyclopenta[c]pyridine-7,2'-pyrrolidine]-4-
yl)acrylate.
(TIF)
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Figure S36.  Preparation of Methyl 3-(1'-methyl-5,6-
dihydrospiro[cyclopenta[c]pyridine-7,2'-pyrrolidine]-4-
yl)propanoate.
(TIF)
Figure S37.  Preparation of 3-(1'-methyl-5,6-
dihydrospiro[cyclopenta[c]pyridine-7,2'-pyrrolidine]-4-
yl)propanoic acid sodium salt (Hapten 9).
(TIF)
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